Page last updated: 2024-11-12
norisoboldine
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
norisoboldine: from Croton lechleri, a source of the wound healing latex sangre de grado; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Related Flora
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Croton | genus | A plant genus of the family EUPHORBIACEAE. The common name of dragon's blood is also used for DRACAENA and Daemonorops (ARECACEAE). Croton tiglium is the source of CROTON OIL.[MeSH] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
| Croton lechleri | species | Common name dragon's blood is used to describe several Croton species and unrelated plants found in Peru and Ecuador. These plants produce a red viscous latex sap commonly referred to as dragon's blood used as a wound healing agent by natives. The principle compound in these saps is alkaloid TASPINE.[MeSH] | Euphorbiaceae | The spurge family of flowering plants in the order Malpighiales. The family consists of annual and perennial herbs and woody shrubs or trees. Members contain securinine.[MeSH] |
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 14539911 |
| CHEMBL ID | 375902 |
| MeSH ID | M0438019 |
Synonyms (24)
| Synonym |
|---|
| CHEMBL375902 |
| S9092 |
| 23599-69-1 |
| norisoboldine |
| AC-34581 |
| Q-100304 |
| AKOS030530135 |
| 4h-dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (s)- |
| HY-N0586 |
| CS-6003 |
| BCP18952 |
| (+)-laurelliptine |
| mfcd09953815 |
| 4h-dibenzo[de,g]quinoline-1,9-diol, 5,6,6a,7-tetrahydro-2,10-dimethoxy-, (6as)- |
| CCG-267616 |
| (6as)-2,10-dimethoxy-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-1,9-diol |
| BS-42172 |
| DTXSID801316226 |
| (+)-norisoboldine |
| (6as)-5,6,6a,7-tetrahydro-2,10-dimethoxy-4h-dibenzo[de,g]quinoline-1,9-diol |
| 6aalpha-noraporphine-1,9-diol, 2,10-dimethoxy- |
| (s)-(+)-laurelliptine |
| 63J46T4EQ3 |
| norisoboldine, (+)- |
Research Excerpts
Overview
Norisoboldine (NOR) is a benzylisoquinoline alkaloid isolated from Radix Linderae, a traditional Chinese medicine. It was shown to be a substrate of P-glycoprotein (P-gp)
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norisoboldine is an important isoquinoline alkaloid found to be present in the dry root of" | ( Therapeutic Importance and Pharmacological Activities of Norisoboldine in Medicine for the Treatment of Human Disorders. Patel, DK; Patel, K, 2023) | 1.88 |
| "Norisoboldine (NOR) is a benzylisoquinoline alkaloid isolated from Radix Linderae, a traditional Chinese medicine. " | ( Norisoboldine attenuates inflammatory pain via the adenosine A1 receptor. Chou, G; Dai, Y; Gao, X; Hu, H; Lu, Q; Pan, R; Wang, Z; Xia, Y, 2014) | 3.29 |
| "Norisoboldine was shown to be a substrate of P-glycoprotein (P-gp), as P-gp inhibitor verapamil markedly increased the permeability coefficient (P" | ( The absorption enhancement of norisoboldine in the duodenum of adjuvant-induced arthritis rats involves the impairment of P-glycoprotein. Dai, Y; Duan, C; Guo, JM; Xia, YF, 2017) | 1.47 |
Effects
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norisoboldine has a biological effect on arthritis, colitis, apoptosis, osteoclast differentiation, inflammatory pain, renal ischemia-reperfusion injury, acute lung injury, pro-inflammatory cytokines, tumor, regulatory T cells, and endothelial cell migration." | ( Therapeutic Importance and Pharmacological Activities of Norisoboldine in Medicine for the Treatment of Human Disorders. Patel, DK; Patel, K, 2023) | 1.88 |
Treatment
| Excerpt | Reference | Relevance |
|---|---|---|
| "Norisoboldine treatment significantly alleviated the severity of the disease, based on the reduced clinical scores and elevated the lowered body weights of model mice." | ( Therapeutic effect of norisoboldine, an alkaloid isolated from Radix Linderae, on collagen-induced arthritis in mice. Chou, G; Dai, Y; Liu, M; Luo, Y; Wang, Z; Xia, Y, 2010) | 1.4 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " This developed method was successfully applied to an in vivo pharmacokinetic study in rats after a single intravenous dose of 10 mg/kg NIB." | ( Simultaneous determination of norisoboldine and its major metabolite in rat plasma by ultra-performance liquid chromatography-mass spectrometry and its application in a pharmacokinetic study. Chen, JZ; Chou, GX; Wang, CH; Wang, ZT; Xu, Y; Yang, L, 2011) | 0.66 |
Bioavailability
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (21)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1764390 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in spleens at 40 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 6.49%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764380 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in colonic lamina proprias at 40 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.97%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764389 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in spleens at 20 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 6.49%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764379 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in colonic lamina proprias at 20 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.97%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764396 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as increase in IL-10 mRNA level at 20 to 40 mg/kg, po administered for 10 consecutive days by Q-PCR analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764359 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as upregulation of Foxp3 mRNA expression at 3 to 30 uM measured after 72 hrs by Q-PCR analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764364 | Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as reduction in DAI score a 20 to 40 mg/kg, po administered for 10 consecutive days | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764373 | Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as protection against colon destruction at 20 to 40 mg/kg, po administered for 10 consecutive days by HE staining based histopathological analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764356 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as number of Treg cells at 30 uM measured after 72 hrs by flow cytometry analysis (Rvb = 24 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764376 | Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as protection against inflammation of colons at 20 to 40 mg/kg, po administered for 10 consecutive days by HE staining based histopathological analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764348 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as upregulation of CD4+ CD25+ cell frequency at 10 uM measured after 72 hrs by flow cytometry analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764370 | Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as reduction in MPO activity at 20 to 40 mg/kg, po administered for 10 consecutive days | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764394 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as increase in Foxp3 mRNA level at 20 to 40 mg/kg, po administered for 10 consecutive days by Q-PCR analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764355 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as number of Treg cells at 10 uM measured after 72 hrs by flow cytometry analysis (Rvb = 24 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764385 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in mesenteric lymph nodes at 40 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.52%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764384 | Induction of Treg cell differentiation in DSS- induced ulcerative colitis mouse model assessed as number of Treg cells in mesenteric lymph nodes at 20 mg/kg, po administered for 10 consecutive days by flow cytometry analysis (Rvb= 7.52%) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764367 | Antiinflammatory activity in DSS-induced ulcerative colitis mouse model assessed as rescue of colon length shortening at 20 to 40 mg/kg, po administered for 10 consecutive days | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764346 | Cytotoxicity against mouse EL4 cells assessed as effect on cell viability at 1 to 10 uM measured after 72 hrs by MTT assay | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764362 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as upregulation of IL-10 mRNA expression at 3 to 30 uM measured after 72 hrs by Q-PCR analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764354 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as number of Treg cells at 3 uM measured after 72 hrs by flow cytometry analysis (Rvb = 24 %) | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| AID1764351 | Induction of cell differentiation in anti-CD3/CD28 stimulated naive T-cells assessed as upregulation of Foxp3 expression at 10 uM measured after 72 hrs by Q-PCR analysis | 2021 | Bioorganic & medicinal chemistry letters, 04-01, Volume: 37 | Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (33)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 21 (63.64) | 24.3611 |
| 2020's | 9 (27.27) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.09) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 33 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||